Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TINAGL1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TINAGL1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View TINAGL1 Products |
| Gene Delivery | TINAGL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View TINAGL1 Products |
| Benchmark Ab | Anti-TINAGL1 Recombinant Monoclonal Antibody Recombinant positive control for flow cytometry, ELISA, and functional block. |
View TINAGL1 Products |
| Validator | TINAGL1 siRNA Set For target knockdown verification in cell-based functional assays. |
View TINAGL1 Products |
| Related Target A | EGFR TINAGL1 acts as a dual inhibitor of integrin and EGFR signaling; EGFR reagents are critical for pathway validation. |
View EGFR Products |
| Related Target B | ITGA5 (Integrin alpha 5) TINAGL1 interacts directly with alpha5beta1 integrin to suppress focal adhesion kinase (FAK) activation. |
View ITGA5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-Domain Protein | HEK293 eukaryotic expression system ensures correct folding of somatomedin B-like and cathepsin B-like domains. |
| Inconsistent Post-Translational Glycosylation | Native glycosylation patterns verified via SDS-PAGE matching theoretical MW shifts. |
| Lack of Reliable Controls | Sequence-verified biosimilar antibodies included for assay bench-marking. |
| Off-Target Pathway Noise | High-specificity siRNA sets included for target-specific knockdown controls. |
Live TINAGL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding Tubulointerstitial Nephritis Antigen-Like 1 (TINAGL1) is gaining traction, particularly in oncology and vascular biology. Known historically as a secreted extracellular matrix protein, recent studies have highlighted its role as a tumor suppressor that simultaneously targets triple-negative breast cancer (TNBC) progression and metastasis by inhibiting both the integrin/FAK and EGFR signaling pathways.
The race for TINAGL1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to recombinant protein therapies and gene therapies designed to restore TINAGL1 expression in the tumor microenvironment. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting the development of bispecific constructs and engineered secretable proteins to overcome local delivery barriers in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | Academic Institutes, Biotech Startups | Triple-Negative Breast Cancer (TNBC) | Integrin Binding Assay (Need high-purity, native-glycosylated ECD-Fc) |
| Monoclonal Antibody | Oncology-focused Biopharma | Angiogenesis & Metastatic Tumors | Epitope Mapping & SPR Binding (Need sequence-verified antigens) |
| Gene Therapy (mRNA/LNP) | RNA Therapeutics Developers | Fibrotic Diseases, Pre-eclampsia | In Vitro Expression Validation (Need validated qPCR/Western blot controls) |